The CONSUL study (ClinicalTrials.gov Identifier: NCT02758782) was an open label study comparing the combined use of NSAIDs and anti-TNF treatment to using anti-TNF therapy alone in patients with ankylosing spondylitis. touchIMMUNOLOGY caught up with Dr Fabian Proft (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the rationale, methodology and the primary endpoint of the study, which assessed the structural damage in the spine over two years and why the primary endpoint was not achieved.
The abstract ‘COmparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-Label, randomized controlled, multicenter trial.’ (Abstract number: OP0018) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What was the rationale for investigating the combined use of NSAIDs and anti-TNF treatment in patients with ankylosing spondylitis? (0:24)
- What was the methodology and eligibility criteria of the CONSUL study? (1:00)
- What was the primary endpoint and how well was it achieved? (1:54)
- Why do you think the primary endpoint was not achieved, and which patient populations might benefit from this combined treatment? (2:51)
- What was the safety and tolerability profile of the combination? (4:15)
Disclosures: Fabian Proft discloses serving on speakers bureaus for AMGEN, AbbVie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Roche and UCB; consulting for Novartis; and receiving grant/research support from Novartis, UCB, and Lilly.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Rheumatic Diseases
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Catherine Sims, ACR 2022: Azathioprine metabolite levels throughout pregnancy in women with rheumatic disease
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!